Showing results (1-10 of 283) with videos related to
Sort By:
Pageof 29
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 30, 2005
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implicationsRobert J Fox, Elizabeth Fisher, Jean Tkach, et al.Neurology|November 12, 2003
Biologic impact of interferon antibodies, and complexities in assessing their clinical significanceRichard A RudickCleveland Clinic Journal of Medicine|November 30, 2011
Multiple sclerosis, natalizumab, and PML: helping patients decideRichard A RudickAlzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's diseaseRichard A RudickJournal of Neuroimaging : Official Journal of the American Society of Neuroimaging|July 2, 2004
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosisRichard A RudickDisease Markers|November 25, 2006
Chemokine receptors as biomarkers in multiple sclerosisRobert J Fox, Pia Kivisäkk, Jar-Chi Lee, et al.Annals of Neurology|April 13, 2007
Imaging correlates of axonal swelling in chronic multiple sclerosis brainsElizabeth Fisher, Ansi Chang, Robert J Fox, et al.Current Opinion in Neurology|April 2, 2011
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugsMegan Hyland, Richard A RudickExpert Review of Neurotherapeutics|April 28, 2005
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MSRichard A Rudick, Alfred SandrockMultiple Sclerosis (Houndmills, Basingstoke, England)|August 13, 2014
Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical databaseDeborah M Miller, Nicolas R Thompson, Jeffrey A Cohen, et al.Pageof 29